Study drug for advanced solid tumors that stopped responding
Part of Cancer clinical trials.
This Phase 1/2 trial studies ZGGS18, a new medicine, in people with advanced solid tumors that either no longer respond to standard treatment or for whom standard treatment isn’t an option. The goal is to see how the drug works and what side effects it causes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor confirmed by a lab test (biopsy or cytology).
- Your usual standard treatments have failed, or you have no standard option, or you couldn’t tolerate standard treatment.
- Your daily function is good: you are fully active or limited only a little (ECOG performance status 0 or 1).
- You expect to live at least 3 months.
- You have at least one measurable tumor spot on scans that can be tracked over time; if a spot was previously treated with radiation, it must have grown again after radiation.
- A study doctor must agree you’re suitable to join (they can exclude you for safety or other concerns).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (ZG005, Gecacitinib, and chemotherapy) for people with advanced solid tumors that cannot be removed by surgery. It aims to see if this combination can shrink tumors or slow their growth.
This trial is testing a new combination of two drugs (ZGGS18 and ZG005) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This Phase 1 trial studies ZG0895.HCl, a new experimental treatment, in people with advanced solid cancers. It’s mainly to check safety and how the body responds, and it may help by shrinking or controlling tumors if the drug works.
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.